Country

Clinical trials in Austria

Active obesity and GLP-1 studies with at least one location in Austria.

26active studies

18recruiting now

28countries represented

628largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Metabolic Dysfunction-Associated Steatotic Liver DiseaseCondition

Tirzepatide, RetatrutideTreatment

Argentina, Australia563 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07165028See eligibility →

Recruiting nowPhase 3

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Ulcerative Colitis, Obesity or OverweightCondition

Mirikizumab, MirikizumabTreatment

Austria, Belgium187 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06937086See eligibility →

Recruiting nowPhase 3

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Crohn's Disease, Obesity or OverweightCondition

Mirikizumab, MirikizumabTreatment

Austria, Belgium183 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06937099See eligibility →

Recruiting nowPhase 3

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

Metabolic Dysfunction Associated SteatohepatitisCondition

Survodutide, Placebo matching survodutideTreatment

Argentina, Australia445 locations

Boehringer IngelheimSponsor

Updated 2026-09-03 · NCT06632457See eligibility →

Recruiting nowPhase 3

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

Obesity, Type 2 DiabetesCondition

Cagrisema, SemaglutideTreatment

Argentina, Australia303 locations

Novo Nordisk A/SSponsor

Updated 2026-08-31 · NCT07564414See eligibility →

Recruiting nowPhase 3

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

Overweight, ObesityCondition

Cagrilintide, SemaglutideTreatment

Australia, Austria121 locations

Novo Nordisk A/SSponsor

Updated 2026-08-31 · NCT07253285See eligibility →

Recruiting nowPhase 3

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver FibrosisCondition

Survodutide, PlaceboTreatment

Argentina, Australia528 locations

Boehringer IngelheimSponsor

Updated 2026-08-21 · NCT06632444See eligibility →

Recruiting nowPhase 3

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection FractionCondition

Maridebart cafraglutide, PlaceboTreatment

Argentina, Australia628 locations

AmgenSponsor

Updated 2026-07-02 · NCT07037459See eligibility →

Recruiting nowNot applicable

Pregnancy Cohort Study: Pregnancy as a Window to Future Health

Healthy Pregnant Women, Obese Pregnant WomenCondition

Intervention not listedTreatment

Austria1 locations

Medical University of GrazSponsor

Updated 2026-04-13 · NCT06925815See eligibility →

Recruiting nowNot applicable

Effects of Akkermansia Muciniphila and Berberine Supplementation on Insulin Sensitivity in Night-shift Workers

Obesity & Overweight, Circadian Rhythm DisordersCondition

Verum (A), Placebo (B)Treatment

Austria1 locations

FH Joanneum Gesellschaft mbHSponsor

Updated 2026-02-27 · NCT07440147See eligibility →

Recruiting nowNot applicable

Metabolic Control of Aging and Disease - the MetAGE Deep Phenotyping Cohort

Obesity, AgingCondition

comprehensive metabolic phenotypingTreatment

Austria2 locations

Thomas SchererSponsor

Updated 2026-02-17 · NCT06511297See eligibility →

Recruiting nowNot applicable

Night Shift Work and Biomarkers of Obesity Risk in Hospital and Industry Workers

Obesity, Shift-work DisorderCondition

No interventionTreatment

Austria1 locations

University of ViennaSponsor

Updated 2025-09-08 · NCT06288568See eligibility →

Recruiting nowNot applicable

Hop Compounds on the Immune System in Overweight People

Inflammatory ResponseCondition

Xanthohumol, Iso-alpha AcidsTreatment

Austria1 locations

University of ViennaSponsor

Updated 2025-04-15 · NCT06745102See eligibility →

Recruiting nowNot applicable

Josef Ressel Centre Perinatal Programming

Childhood ObesityCondition

observationTreatment

Austria1 locations

Moenie van der KleynSponsor

Updated 2025-03-17 · NCT03634930See eligibility →

Recruiting nowNot applicable

Cohort Study on Plant-based Diets (COPLANT Study)

Dietary Exposure, Diabetes Mellitus, Type 2Condition

Intervention not listedTreatment

Austria, Germany8 locations

German Federal Institute for Risk AssessmentSponsor

Updated 2025-02-14 · NCT06323538See eligibility →

Recruiting nowNot applicable

ESAN II - Energy Sensing in Depression

Immune System Tolerance, DepressionCondition

Aronia Juice, PlaceboTreatment

Austria1 locations

Medical University of GrazSponsor

Updated 2024-11-27 · NCT05432362See eligibility →

Recruiting nowNot applicable

AI-POD Clinical Validation Study for Obese Patients

Acute Cardiovascular DiseaseCondition

Non InterventionalTreatment

Austria, Belgium6 locations

University Hospital, BonnSponsor

Updated 2024-09-19 · NCT06595134See eligibility →

Recruiting nowPhase 4

Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Overweight/Obese Men With T2DM or Prediabetes and Hypogonadism

Fatty Liver, Overweight/ObesityCondition

Testosterone Undecanoate, PlaceboTreatment

Austria1 locations

Alexandra Kautzky-WillerSponsor

Updated 2024-03-13 · NCT03851627See eligibility →

Opening soonNot applicable

Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN)

Severe Mental Illness, Depression / Major Depressive DisorderCondition

Semaglutide (SEMA), Exercise moduleTreatment

Austria, Germany5 locations

Ludwig-Maximilians - University of MunichSponsor

Updated 2026-05-14 · NCT07586150See eligibility →

Active, not recruitingPhase 3

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)

Non-alcoholic SteatohepatitisCondition

Semaglutide, PlaceboTreatment

Argentina, Australia558 locations

Novo Nordisk A/SSponsor

Updated 2026-09-04 · NCT04822181See eligibility →

Active, not recruitingPhase 1, Phase 2

A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight

Overweight and ObesityCondition

AZD9550, placeboTreatment

Austria, Canada15 locations

AstraZenecaSponsor

Updated 2026-08-26 · NCT06151964See eligibility →

Active, not recruitingPhase 3

A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight

ObesityCondition

Semaglutide, PlaceboTreatment

Austria, Belgium56 locations

Novo Nordisk A/SSponsor

Updated 2026-08-07 · NCT05726227See eligibility →

Active, not recruitingPhase 2

A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Overweight, ObesityCondition

Tirzepatide, PlaceboTreatment

Austria, Canada27 locations

Eli Lilly and CompanySponsor

Updated 2026-05-08 · NCT05536804See eligibility →

Active, not recruitingNot applicable

Cardiovascular and InflammAging Study

Aging, Cardiovascular DiseasesCondition

Juice Plus+ Fruit, Vegetable and Berry blends, Juice Plus+ Omega blendTreatment

Austria2 locations

Green BeatSponsor

Updated 2025-07-01 · NCT04763291See eligibility →

Active, not recruitingNot applicable

ESAN III - Energy Sensing in Depression

Obesity, Gut Microbiota ModulationCondition

Carotenoid-rich juice, ControlTreatment

Austria1 locations

Medical University of GrazSponsor

Updated 2025-06-27 · NCT06985381See eligibility →

Active, not recruitingNot applicable

Multinational Point Prevalence Study on the Management of Diabesity in Hospitals

Diabetes Mellitus, ObesityCondition

Routine care for people with diabetes, with or without obesity, in the hospital settingTreatment

Austria, Czechia8 locations

Medical University of ViennaSponsor

Updated 2025-05-08 · NCT06680674See eligibility →

Related countries

United States1,107 China326 Canada158 France110 Spain98 Germany95

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.